To investigate whether targeting laIL-2 to the tumor site via PD-1 can exert better tumor control than other potential non-T cell targets, we linked laIL-2 to an anti–PD-L1 antibody (PD-L1–laIL-2). Here, CD274 is linked to neoplasm.